Mesoblast (ASX:MSB), (NASDAQ:MESO) is a biopharmaceutical company focused on developing and commercializing innovative allogeneic cellular medicines to treat severe and life-threatening conditions. The company's products are based on its proprietary mesenchymal lineage cell therapy technology, which aims to provide significant improvements for patients suffering from inflammatory ailments, cardiovascular diseases, and back pain. Mesoblast's pipeline includes several late-stage clinical candidates targeting conditions such as acute graft versus host disease, chronic heart failure, and chronic low back pain. Their objective is to harness the power of cells to regenerate tissues and organs and to provide life-changing treatments for patients who have limited options. Mesoblast is also traded on the Australian Securities Exchange (ASX:MSB), highlighting its global presence and commitment to advancing healthcare through innovative medical research.